Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash from Financing Activities (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Cash from Financing Activities data on record, last reported at $1.1 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 117.42% year-over-year to $1.1 million; the TTM value through Dec 2025 reached -$89.7 million, down 169.81%, while the annual FY2025 figure was -$89.7 million, 169.81% down from the prior year.
  • Cash from Financing Activities reached $1.1 million in Q4 2025 per TGTX's latest filing, up from -$78.2 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $134.5 million in Q3 2024 and bottomed at -$78.2 million in Q3 2025.
  • Average Cash from Financing Activities over 5 years is $7.6 million, with a median of $29500.0 recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: soared 34749.63% in 2023, then tumbled 607100.0% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $56.0 million in 2021, then crashed by 99.91% to $49000.0 in 2022, then crashed by 102.04% to -$1000.0 in 2023, then crashed by 607100.0% to -$6.1 million in 2024, then skyrocketed by 117.42% to $1.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $1.1 million in Q4 2025, -$78.2 million in Q3 2025, and -$6.4 million in Q2 2025.